Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M)
V Chounta, ET Overton, A Mills, S Swindells… - The Patient-Patient …, 2021 - Springer
Background Advances in HIV-1 therapeutics have led to the development of a range of daily
oral treatment regimens, which share similar high efficacy rates. Consequently, more …
oral treatment regimens, which share similar high efficacy rates. Consequently, more …
Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
S Swindells, T Lutz, L Van Zyl, N Porteiro, M Stoll… - Aids, 2022 - journals.lww.com
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study,
demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long …
demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long …
Patient-reported tolerability and acceptability of cabotegravir+ rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized …
M Murray, F Pulido, A Mills, M Ramgopal… - HIV Research & …, 2019 - Taylor & Francis
Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality
currently under development as an alternative to daily oral ART. Objective: The LATTE-2 …
currently under development as an alternative to daily oral ART. Objective: The LATTE-2 …
Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks
M Murray, A Antela, A Mills, J Huang, H Jäger… - AIDS and Behavior, 2020 - Springer
The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting
(LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current …
(LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current …
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy
A Mills, GJ Richmond, C Newman, O Osiyemi, J Cade… - Aids, 2022 - journals.lww.com
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …
demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a …
ET Overton, G Richmond, G Rizzardini… - Clinical Infectious …, 2023 - academic.oup.com
Abstract Background Cabotegravir (CAB)+ rilpivirine (RPV) dosed intramuscularly monthly
or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 …
or every 2 months is a complete, long-acting (LA) regimen for the maintenance of HIV-1 …
Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 …
GHR Smith, WK Henry, D Podzamczer… - Open Forum …, 2021 - academic.oup.com
Abstract Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2)
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …
phase 2b study, long-acting (LA) injectable cabotegravir+ rilpivirine dosed every 8 weeks …
Perspectives of people living with HIV‐1 on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III …
CP Garris, M Czarnogorski… - Journal of the …, 2022 - Wiley Online Library
Abstract Introduction The CUSTOMIZE hybrid III implementation‐effectiveness study
evaluated implementation of once‐monthly long‐acting (LA) cabotegravir+ rilpivirine in …
evaluated implementation of once‐monthly long‐acting (LA) cabotegravir+ rilpivirine in …
[HTML][HTML] Long-acting injectable cabotegravir+ rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials
G Rizzardini, ET Overton, C Orkin… - JAIDS Journal of …, 2020 - journals.lww.com
Background: Long-acting (LA) injectable regimens are a potential therapeutic option in
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …
people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were …
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label …
ET Overton, G Richmond, G Rizzardini, H Jaeger… - The Lancet, 2020 - thelancet.com
Background Phase 3 clinical studies showed non-inferiority of long-acting intramuscular
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …